Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $923,000.

  • Allogene Therapeutics' Amortizatization of Intangibles fell 45.67% to $923,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 49.47%. This contributed to the annual value of $8.3 million for FY2024, which is 22.60% up from last year.
  • As of Q3 2025, Allogene Therapeutics' Amortizatization of Intangibles stood at $923,000, which was down 21.18% from $1.2 million recorded in Q2 2025.
  • Allogene Therapeutics' Amortizatization of Intangibles' 5-year high stood at $3.3 million during Q4 2023, with a 5-year trough of -$1.9 million in Q1 2021.
  • For the 3-year period, Allogene Therapeutics' Amortizatization of Intangibles averaged around $1.7 million, with its median value being $1.7 million (2024).
  • Per our database at Business Quant, Allogene Therapeutics' Amortizatization of Intangibles slumped by 3,176.79% in 2021 and then soared by 2,214.74% in 2023.
  • Allogene Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$1.6 million in 2021, then spiked by 90.21% to -$156,000 in 2022, then surged by 2,214.74% to $3.3 million in 2023, then tumbled by 49.95% to $1.7 million in 2024, then tumbled by 45.67% to $923,000 in 2025.
  • Its last three reported values are $923,000 in Q3 2025, $1.2 million for Q2 2025, and $1.3 million during Q1 2025.